玻璃体切割术中注射雷珠单抗0.5 mg与1.0 mg治疗增殖性糖尿病视网膜病变的疗效与安全性比较:一项随机对照试验
这项前瞻性6个月随机对照试验纳入80例87眼需行玻璃体切割术的增殖性糖尿病视网膜病变患者,随机分为术中注射雷珠单抗1.0 mg组与0.5 mg组。1.0 mg组早期术后玻璃体积血分级更轻、复发率更低(35.0% vs 63.4%,P=0.0195),两组最佳矫正视力均较基线显著改善但组间无显著差异(P=0.74),黄斑中心凹厚度降低幅度及术后不良事件概率组间无显著差异。
要点
- 1.0 mg组早期术后玻璃体积血复发率35.0%,低于0.5 mg组的63.4%(P=0.0195)。
- 两组最佳矫正视力从基线至术后6个月均显著改善,但组间差异无统计学意义(P=0.74)。
- 两组黄斑中心凹厚度平均降低幅度及术后不良事件概率均无显著差异。
核心结论
- 玻璃体切割术后玻璃体腔内注射雷珠单抗1.0 mg较推荐剂量0.5 mg显著降低增殖性糖尿病视网膜病变患者早期术后玻璃体积血的复发率和严重程度,并有助于术后早期视力恢复,且未增加术后不良事件。
研究设计与样本
- 前瞻性、6个月、随机对照试验,纳入80例87眼需行玻璃体切割术治疗的增殖性糖尿病视网膜病变患者,随机分为1.0 mg注射组和0.5 mg注射组,雷珠单抗于术中手术结束时注射。
主要发现
- 1.0 mg组早期术后玻璃体积血分级较0.5 mg组更轻,复发率分别为35.0%和63.4%(P=0.0195)。
- 1.0 mg组最佳矫正视力从基线1.60±0.72 LogMAR(<20/200)改善至术后6个月0.47±0.49 LogMAR(20/59),0.5 mg组从1.51±0.69 LogMAR(<20/200)改善至0.50±0.31 LogMAR(20/63),组间差异无统计学意义(P=0.74)。
- 两组黄斑中心凹厚度平均降低幅度及术后不良事件概率均无显著差异。
关键数值与推荐
- 早期术后玻璃体积血复发率:1.0 mg组35.0% vs 0.5 mg组63.4%(P=0.0195)。
- 最佳矫正视力组间比较P=0.74,无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the effectiveness of two regimens of ranibizumab-assisted pars plana vitrectomy in the treatment of patients with proliferative diabetic retinopathy. METHODS: This is a prospective, 6-month, randomized controlled trial. Eighty patients with 87 eyes requiring pars plana vitrectomy treatment for proliferative diabetic retinopathy were included and randomly divided into a 1.0-mg injection group and a 0.5-mg injection group. The ranibizumab was delivered intraoperatively, at the close of surgery. The vitreous hemorrhage grade, best-corrected visual acuity, central macular thickness, and safety data were assessed to Month 6. RESULTS: The 1.0-mg injection group had a milder grade and a lower reoccurrence rate of early postoperatively vitreous hemorrhage than the 0.5-mg injection group (35.0% and 63.4%, respectively, P = 0.0195). The mean best-corrected visual acuity of two groups was significantly improved from baseline to 6 months after surgery, 1.60 ± 0.72 Logarithm of the Minimum Angle of Resolution (LogMAR) (<20/200) to 0.47 ± 0.49 LogMAR (20/59) for the 1.0-mg injection group and 1.51 ± 0.69 LogMAR (<20/200) to 0.50 ± 0.31 LogMAR (20/63) for the 0.5-mg injection group, but there was no significant difference between the two groups ( P = 0.74). There was no significant difference in the mean decrease in central macular thickness and probability of postoperative adverse events between the two groups. CONCLUSION: Intravitreal injection of 1.0 mg of ranibizumab after pars plana vitrectomy compared with the recommended dose of 0.5 mg significantly reduced the recurrence and severity of early postoperative vitreous hemorrhage in patients with proliferative diabetic retinopathy. It also contributed to the early recovery of visual acuity after surgery and did not increase postoperative adverse events.
引用
- Su T, Lai D, Wu Y, et al. COMPARISON OF THE EFFICACY AND SAFETY OF RANIBIZUMAB 0.5 MG VERSUS 1.0 MG WITH PARS PLANA VITRECTOMY FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY: A Randomized Controlled Trial. Retina. 2024. PMID: 38011844. doi:10.1097/IAE.0000000000003998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。